A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors

Inclusion Criteria: * Patients voluntarily participate in the clinical trial and sign the informed consent form * Age 18 years and above (inclusive), and below 75 years of age (inclusive), with no gender restrictions * ECOG(Eastern Cooperative Oncology Group)performance status of 0 or 1 * Expected survival time of ≥3 months * During the screening period, female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to administration of the study drug * Participants agree to use reliable contraception methods from signing the informed consent form until 6 months after the last dose of the study drug. This includes, but is not limited to: abstinence, vasectomy in males, female sterilization, effective intrauterine devices, and effective contraceptive medications Exclusion Criteria: * Participants have not recovered to normal or ≤ Grade 1 from any adverse events and/or complications caused by any previous treatments before the first administration of the study drug, excluding hair loss and pigmentation * Patients with imaging (CT or MRI) showing tumor invasion into major blood vessels (such as the aorta, pulmonary arteries and veins, vena cava, etc.) * Patients who have had clinically significant cardiovascular or cerebrovascular diseases within 6 months before the first administration, which, in the investigator's judgment, may interfere with the patient's full participation in the study; atrial fibrillation; clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention * Patients who had history of type 1 diabetes, type 2 diabetes, or gestational diabetes * Individuals with other malignancies or with a history of other malignant tumors * Individuals with a history of severe allergies, or who are allergic to any active or inactive ingredients of the study drug * Pregnant or breastfeeding patients * Researchers consider participants unsuitable for this clinical study due to any clinical or laboratory abnormalities or other reasons